TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16960941

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg qd
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg qd
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg bid
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study: 12631041

Group type: EXPERIMENTAL
Intervention: i.v. propacetamol 40 mg kg(‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: i.v. propacetamol 20 mg kg(‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: i.v. propacetamol 10 mg kg(‐1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups (H, I, L)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: i.v. propacetamol
Number of subjects: 64
Study: 11789281

Group type: EXPERIMENTAL
Intervention: Angelica sinensis injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% glucose injection
Number of subjects: 60
Study: 9089558

Group type: EXPERIMENTAL
Intervention: Menorest
Number of subjects: 275

Group type: COMPARATOR
Intervention: Estraderm TTS
Number of subjects: 275
Study: 7682581

Group type: EXPERIMENTAL
Intervention: Antigen challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Codeine challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buffer diluent
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antigen challenge after codeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation with immunoglobulin G levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation with histamine levels
Number of subjects: 10
Study: 3535010

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at night
Number of subjects: 59

Group type: COMPARATOR
Intervention: 150 mg ranitidine twice daily
Number of subjects: 59
Study: 30295410

Group type: EXPERIMENTAL
Intervention: Patient Controlled Sedation (PCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiologist Controlled Sedation (RCS)
Number of subjects: 40
Study: 26661319

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL up-titrated to 200 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 24573506

Group type: EXPERIMENTAL
Intervention: Immediate IUD insertion after abortion under general or paracervical anesthesia
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed IUD insertion during the next menstrual cycle without anesthesia
Number of subjects: 142
Study: 22429325

Group type: EXPERIMENTAL
Intervention: Self-efficacy promotion training programme (six sessions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 63
Study: 19608185

Group type: EXPERIMENTAL
Intervention: Probiotic strain L. plantarum (DSM 9843)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18804887

Group type: EXPERIMENTAL
Intervention: Empowerment-based educational system (LAY)
Number of subjects: 89
Study: 15690537

Group type: EXPERIMENTAL
Intervention: Tac / steroids
Number of subjects: 698

Group type: COMPARATOR
Intervention: Tac / Dac
Number of subjects: 698
Study: 12395004

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 73

Group type: COMPARATOR
Intervention: No Ultrasound (Control)
Number of subjects: 73
Study: 11871829

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (80 mg intramuscularly once weekly for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral prednisolone (40 mg/day in a 'tailing‐off' regimen)
Number of subjects: 40
Study: 9647268

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg via metered-dose inhaler twice daily
Number of subjects: 539

Group type: COMPARATOR
Intervention: Albuterol 180 microg four times daily
Number of subjects: 539
Study: 7718048

Group type: EXPERIMENTAL
Intervention: Medline search for randomised clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted means for sensitivity across all studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted mean for precision
Number of subjects: 0
Study: 2493023

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg, orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31192625

Group type: EXPERIMENTAL
Intervention: Experimental treatments using logarithmic‐transformed ANOVA (LANOVA) and logarithmic‐transformed ANCOVA (LANCOVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed methods (LANOVA and LANCOVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logarithmic transformations
Number of subjects: 0
Study: 30654026

Group type: EXPERIMENTAL
Intervention: App+Coach
Number of subjects: 180

Group type: COMPARATOR
Intervention: App
Number of subjects: 180

Group type: COMPARATOR
Intervention: Clinic
Number of subjects: 180
Study: 28427388

Group type: COMPARATOR
Intervention: Standard Speech Therapy (SST) for 45 minutes, twice a week for 9 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement, Cognition and Narration of emotions treatment (MCNT) for 3 hours per day, 5 days a week for 9 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list for Standard Speech Therapy (SST) for 9 months
Number of subjects: 0
Study: 25256361

Group type: EXPERIMENTAL
Intervention: Dialogical exposure group treatment using Gestalt empty‐chair method
Number of subjects: 119

Group type: COMPARATOR
Intervention: Supportive group treatment
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Dialogical exposure group treatment
Number of subjects: 119
Study: 23895180

Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) ON
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gastric electrical stimulation (GES) OFF
Number of subjects: 32
Study: 21439633

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h)
Number of subjects: 20111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20111
Study: 17998903

Group type: EXPERIMENTAL
Intervention: Energy-deficit
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Energy-replacement
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 17164546

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 70
Study: 12918131

Group type: EXPERIMENTAL
Intervention: Regimen 2 (saccharomyces boulardii 250 mg Tid + metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Regimen 1 (metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Number of subjects: 54
Study: 10889424

Group type: EXPERIMENTAL
Intervention: AcrySof 5.5 mm
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: AcrySof 6.0 mm
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: SI-40
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (presbyopia only)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 302
Study: 9127654

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 107

Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 107

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 107
Study: 8413982

Group type: EXPERIMENTAL
Intervention: Anticipatory cerebral events related to the most frequently occurring stimulus; measured by premovement potentials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response to the least probable stimulus; measured by accuracy and speed of response.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebral potentials measured by scalp distribution after unexpected stimulus occurrence.
Number of subjects: 0
Study: 29348010

Group type: EXPERIMENTAL
Intervention: Evolut PRO valve
Number of subjects: 60
Study: 27172483

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 25436769

Group type: EXPERIMENTAL
Intervention: IV 1-2×10(6) bone-marrow-derived MSCs/Kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21959100

Group type: EXPERIMENTAL
Intervention: Lively Legs program
Number of subjects: 184

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 184
Study: 19659665

Group type: EXPERIMENTAL
Intervention: Allopurinol mouth rinse (1 mg/ml)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18570643

Group type: EXPERIMENTAL
Intervention: Family assisted exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 40
Study: 16005976

Group type: EXPERIMENTAL
Intervention: Sharp-edged IOL (Sensar AR40e)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Rounded-edge IOL (Sensar AR40)
Number of subjects: 75
Study: 12454616

Group type: EXPERIMENTAL
Intervention: Video plus information leaflet
Number of subjects: 124

Group type: COMPARATOR
Intervention: Information leaflet alone
Number of subjects: 124
Study: 10604042

Group type: COMPARATOR
Intervention: Ginkgo biloba extract EGb 761 120 mg/d
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 240 mg/d
Number of subjects: 74
Study: 8770319

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg once daily for 6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily for 6 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 26
Study: 1682226

Group type: EXPERIMENTAL
Intervention: 200 mg D,L-kawain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg D,L-kawain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg D,L-kawain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7137521

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (100 micrograms daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31594892

Group type: EXPERIMENTAL
Intervention: Receiving incidental results from genomic sequencing
Number of subjects: 260

Group type: COMPARATOR
Intervention: Not receiving incidental results from genomic sequencing
Number of subjects: 260
Study: 30245281

Group type: EXPERIMENTAL
Intervention: FDC 975/292.5
Number of subjects: 408

Group type: COMPARATOR
Intervention: Acetaminophen 975 mg
Number of subjects: 408

Group type: COMPARATOR
Intervention: Ibuprofen 292.5 mg
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 408
Study: 26916487

Group type: EXPERIMENTAL
Intervention: Public reporting of hospital readmission rates (CMS implementation)
Number of subjects: 217094
Study: 25230866

Group type: EXPERIMENTAL
Intervention: 3-hour extended infusion of meropenem (1 g dissolved in 40 mL saline, followed by 750 mg continuous infusion for 3 hours, repeated every 8 hours)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 30-minute infusion of meropenem (1 g dissolved in 40 mL saline, intravenous infusion within 30 minutes every 8 hours)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 3-hour extended infusion of meropenem
Number of subjects: 78

Group type: COMPARATOR
Intervention: 30-minute infusion of meropenem
Number of subjects: 78
Study: 22391671

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard tube
Number of subjects: 40
Study: 20002472

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTT)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Isolated impaired glucose tolerance
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Isolated impaired fasting glucose
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Age, parental diabetes, body mass index, uric acid, current smoking, HbA(1c), fasting and 2-h glucose (OGTT)
Number of subjects: 887
Study: 17480223

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (No-MBP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups (MBP and No-MBP)
Number of subjects: 105
Study: 14997083

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.01 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions (sufentanil and remifentanil)
Number of subjects: 60
Study: 11642080

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once a day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diltiazem (120-180 mg twice a day)
Number of subjects: 31
Study: 9724072

Group type: EXPERIMENTAL
Intervention: 30 microg EE2 combined with 75 microg gestodene (EE2/GSD)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30 microg EE2 combined with 150 microg desogestrel (EE2/DES)
Number of subjects: 47
Study: 8030850

Group type: EXPERIMENTAL
Intervention: Antagonic-Stress (AS) composition
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nicergoline (NE)
Number of subjects: 62
Study: 2480576

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1000 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 750 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg
Number of subjects: 21
Study: 31177406

Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd:YAG 1064-nm laser (LFQS 1064-nm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Q-switched Nd:YAG 532-nm laser (QS 532-nm)
Number of subjects: 30
Study: 30508090

Group type: EXPERIMENTAL
Intervention: Antidepressant treatments + brexpiprazole
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Antidepressant treatments + placebo
Number of subjects: 2066
Study: 28329859

Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 2390

Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2390

Group type: EXPERIMENTAL
Intervention: Speed of processing training with booster sessions
Number of subjects: 2390

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2390

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 2390
Study: 25660106

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with 5 methyl‐aminolevulinate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Trichloroacetic acid 50%
Number of subjects: 13
Study: 24802654

Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin with cetuximab (GC + CTX)
Number of subjects: 88
Study: 22968058

Group type: EXPERIMENTAL
Intervention: cutaneous lysate skin cream applied twice daily for 3 months
Number of subjects: 30
Study: 19296743

Group type: EXPERIMENTAL
Intervention: Dietary intervention (plant-based diet)
Number of subjects: 2254

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 2254
Study: 17961086

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study: 15871655

Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effective therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trial results
Number of subjects: 0
Study: 12134984

Group type: EXPERIMENTAL
Intervention: Conjunctival rotation autograft (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conjunctival autograft (Group B)
Number of subjects: 31
Study: 9792296

Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 1897
Study: 7890059

Group type: EXPERIMENTAL
Intervention: RU486 (50 mg daily for 6 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (normal cycling women in the follicular phase)
Number of subjects: 18
Study: 2098016

Group type: EXPERIMENTAL
Intervention: Immunotherapy with insect venom
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 242
Study: 491472

Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% combined with 0.05% dipivalyl-epinephrine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% combined with 0.1% dipivalyl-epinephrine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pilocarpine 1%
Number of subjects: 2
Study: 31520215

Group type: EXPERIMENTAL
Intervention: Treadmill walking at 0.89 m/s for 4 minutes
Number of subjects: 29
Study: 28439893

Group type: EXPERIMENTAL
Intervention: Re-induction therapy (including fludarabine, cytarabine ± anthracyclines)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) as consolidation therapy after relapse
Number of subjects: 543

Group type: COMPARATOR
Intervention: No SCT as part of relapse therapy
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Intensive re-induction followed by SCT
Number of subjects: 543
Study: 26022214

Group type: EXPERIMENTAL
Intervention: Partially defatted Granulated Brazil nut (GBN) 13 g per day (≈227.5 μg/day of selenium)
Number of subjects: 91
Study: 23972450

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21606391

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13420

Group type: EXPERIMENTAL
Intervention: Serious bleeding events
Number of subjects: 13420
Study: 19404724

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (CBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Support strategy
Number of subjects: 67
Study: 16778713

Group type: EXPERIMENTAL
Intervention: Cicloral (CIC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neoral (NEO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cmax for Cicloral (CIC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urinary recovery of CyA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: N‐demethylated metabolite AM4N
Number of subjects: 12
Study: 15308881

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor therapy
Number of subjects: 635

Group type: COMPARATOR
Intervention: Blood pressure treatment strategy achieving 128/78 mm Hg (low blood pressure goal)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Recruitment through screening in clinical practice
Number of subjects: 635
Study: 10401453

Group type: EXPERIMENTAL
Intervention: Medication-free period (4 weeks)
Number of subjects: 31
Study: 7674179

Group type: COMPARATOR
Intervention: Group 1 (no surface treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Group 3 (saliva-contaminated)
Number of subjects: 15
Study: 2213868

Group type: EXPERIMENTAL
Intervention: High-risk sexual behavior index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social context variables (family structure, parenting practices, friends' engagement in problem behaviors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem behaviors and social context variables
Number of subjects: 0
Study: 7406949

Group type: EXPERIMENTAL
Intervention: Probucol (4 X 250 mg per day for 4 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31504694

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin A (VA)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 306
Study: 30296404

Group type: EXPERIMENTAL
Intervention: Polychromatic blue-enriched light (17,000 K)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard white polychromatic light (4000 K)
Number of subjects: 20
Study: 28432376

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg MDMA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MDMA
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25132461

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 3% topical gel
Number of subjects: 360

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 360
Study: 22782343

Group type: EXPERIMENTAL
Intervention: Huachansu plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with huachansu 20 ml m(‐2) daily for 21 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with placebo)
Number of subjects: 80
Study: 20437680

Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 17984856

Group type: EXPERIMENTAL
Intervention: Anticonvulsants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 0
Study: 16319406

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 263

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 263
Study: 12071241

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 100
Study: 10548627

Group type: EXPERIMENTAL
Intervention: recFSH supplemented medium
Number of subjects: 143

Group type: COMPARATOR
Intervention: simple medium
Number of subjects: 143
Study: 8847279

Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 12
Study: 1973879

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 140 mg/day (Group I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 270 mg/day (Group II)
Number of subjects: 24
Study: 6273551

Group type: EXPERIMENTAL
Intervention: Otosporin (antibiotic/steroid ear drops)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Aluminium acetate ear drops
Number of subjects: 126
Study: 30425095

Group type: EXPERIMENTAL
Intervention: Nonsevere hypoglycemia
Number of subjects: 11495

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 11495
Study: 27395330

Group type: EXPERIMENTAL
Intervention: Nutritional treatment + synbiotic (Lactobacillus and Bifidobacterium strains + 6 g fructooligosaccharides)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nutritional treatment + placebo (6 g maltodextrin)
Number of subjects: 64
Study: 26244563

Group type: EXPERIMENTAL
Intervention: Intralesional botulinum toxin A (5 U per 1 cm2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intralesional saline placebo
Number of subjects: 18